First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours

Autor: Keilholz, U., Rohde, L., Mehlitz, P., Knoedler, M., Schmittel, A., Kümmerlen, V., Klinghammer, K., Treasure, P., Lassus, M., Steventon, G., Machacek, M., Utku, N.

Publikováno v: In European Journal of Cancer July 2017 80:14-25

Kamenev-type criteria for nonlinear second-order delay dynamic equations

Autor: Şenel, M. T., Utku, N., El-Sheikh, M. M. A., Li, T.

Publikováno v: Volume: 47, Issue: 2 339-345
Hacettepe Journal of Mathematics and Statistics
Scopus-Elsevier

We study oscillation of certain second-order nonlinear delay dynamic equations on arbitrary time scales. Employing a class of kernel functions, new Kamenev-type oscillation criteria are presented that differ from the known ones. These criteria improv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c884186c7d17749708b86ce44445670c
https://avesis.erciyes.edu.tr/publication/details/6f0aaaac-18ad-423e-9cf4-35af9ed28df0/oai

The Transmembrane Receptor TIRC7 Identifies a Distinct Subset of Immune Cells with Prognostic Implications in Cholangiocarcinoma.

Autor: Albrecht T; Institute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.; Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany., Goeppert B; Institute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.; Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany., Brinkmann F; Institute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.; Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany., Charbel A; Institute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.; Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany., Zhang Q; Institute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.; Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany., Schreck J; Institute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.; Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany., Wilhelm N; Tissue Bank of the National Center for Tumor Diseases, Heidelberg University Hospital, 69120 Heidelberg, Germany., Singer S; Institute of Pathology and Neuropathology, Eberhard-Karls University, 72076 Tübingen, Germany., Köhler BC; Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany.; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, 69120 Heidelberg, Germany., Springfeld C; Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany.; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, 69120 Heidelberg, Germany., Mehrabi A; Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany.; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany., Schirmacher P; Institute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.; Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany., Kühl AA; Charité-Universitätsmedizin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, iPATH.Berlin, 12203 Berlin, Germany., Vogel MN; Diagnostic and Interventional Radiology, Thoraxklinik at Heidelberg University Hospital, 69126 Heidelberg, Germany., Jansen H; Institute for Medical Immunology, Campus Virchow, Charité, Augustenburger Platz 1, 13353 Berlin, Germany., Utku N; Institute for Medical Immunology, Campus Virchow, Charité, Augustenburger Platz 1, 13353 Berlin, Germany., Roessler S; Institute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany.; Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany.

Publikováno v: Cancers [Cancers (Basel)] 2021 Dec 14; Vol. 13 (24). Date of Electronic Publication: 2021 Dec 14.

Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study.

Autor: Pape UF; Department of Hepatology and Gastroenterology, Campus Charité Mitte and Virchow Klinikum, Charité Universitätsmedizin Berlin, 10117 Berlin, Germany.; Germany and Department of Internal Medicine and Gastroenterology, Asklepios Klinik St. Georg, Asklepios Tumorzentrum, Hamburg ATZHH, 20099 Hamburg, Germany., Kasper S; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, 45147 Essen, Germany., Meiler J; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, 45147 Essen, Germany., Sinn M; Department of Medical Oncology, Universitäts Klinikum Hamburg-Eppendorf, 20251 Hamburg, Germany.; Department of Gastroenterology, Campus Charité Mitte and Virchow Klinikum, Charité Universitätsmedizin Berlin, 10117 Berlin, Germany., Vogel A; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, 30625 Hannover, Germany., Müller L; Onkologische Schwerpunktpraxis Leer-Emden-Papenburg, 26789 Leer, Germany., Burkhard O; Onkologische Praxis, 67547 Worms, Germany., Caca K; Klinikum Ludwigsburg, 71640 Ludwigsburg, Germany., Heeg S; Department of Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Diseases, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 70085 Freiburg, Germany., Büchner-Steudel P; Martin-Luther-University Halle Wittenberg, Medizinische Fakultät, Universitätsklinik und Poliklinik für Innere Medizin I, 06120 Halle (Saale), Germany., Rodriguez-Laval V; Hospital Universitario de La Princesa, 28006 Madrid, Spain., Kühl AA; iPATH.Berlin, Core Unit of the Charité, Hindenburgdamm, 12203 Berlin, Germany., Arsenic R; Instituts für Histologische und Zytologische Diagnostik AG, 5000 Aarau, Switzerland., Jansen H; Institute for Medical Immunology, Charité Universitätsmedizin Berlin, 13353 Berlin, Germany., Treasure P; Peter Treasure Statistical Services Ltd., Stow Bridge PE34 3NR, UK., Utku N; Instituts für Histologische und Zytologische Diagnostik AG, 5000 Aarau, Switzerland.; CellAct Pharma, 44137 Dortmund, Germany.

Publikováno v: Cancers [Cancers (Basel)] 2020 Oct 27; Vol. 12 (11). Date of Electronic Publication: 2020 Oct 27.

Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma.

Autor: Goeppert B; Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, Heidelberg, Germany. benjamin.goeppert@med.uni-heidelberg.de.; Liver Cancer Center Heidelberg (LCCH), University Hospital Heidelberg, Heidelberg, Germany. benjamin.goeppert@med.uni-heidelberg.de., Renner M; Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, Heidelberg, Germany., Singer S; Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, Heidelberg, Germany.; Liver Cancer Center Heidelberg (LCCH), University Hospital Heidelberg, Heidelberg, Germany., Albrecht T; Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, Heidelberg, Germany.; Liver Cancer Center Heidelberg (LCCH), University Hospital Heidelberg, Heidelberg, Germany., Zhang Q; Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, Heidelberg, Germany., Mehrabi A; Liver Cancer Center Heidelberg (LCCH), University Hospital Heidelberg, Heidelberg, Germany.; Department of General Visceral and Transplantation Surgery, University Hospital Heidelberg, Im Neuenheimer Feld 110, Heidelberg, Germany., Pathil A; Department of Internal Medicine IV, Gastroenterology and Hepatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, Heidelberg, Germany., Springfeld C; Liver Cancer Center Heidelberg (LCCH), University Hospital Heidelberg, Heidelberg, Germany.; University Hospital Heidelberg, National Center for Tumor Diseases, Department of Medical Oncology, Heidelberg, Germany., Köhler B; Liver Cancer Center Heidelberg (LCCH), University Hospital Heidelberg, Heidelberg, Germany.; University Hospital Heidelberg, National Center for Tumor Diseases, Department of Medical Oncology, Heidelberg, Germany., Rupp C; Liver Cancer Center Heidelberg (LCCH), University Hospital Heidelberg, Heidelberg, Germany.; Department of Internal Medicine IV, Gastroenterology and Hepatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, Heidelberg, Germany., Weiss KH; Liver Cancer Center Heidelberg (LCCH), University Hospital Heidelberg, Heidelberg, Germany.; Department of Internal Medicine IV, Gastroenterology and Hepatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, Heidelberg, Germany., Kühl AA; Department of Gastroenterology-Immunpathology, Institute for Medical Immunology, Campus Steglitz, Berlin, Charité, Germany., Arsenic R; Department of Pathology, Institute for Medical Immunology, Campus Mitte, Berlin, Charité, Germany., Pape UF; Asklepios Klinik St. Georg, Asklepios Kliniken Hamburg GmbH, Hamburg, Germany., Vogel A; Department of Internal Medicine, Medizinische Hochschule Hannover, Hannover, Germany., Schirmacher P; Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, Heidelberg, Germany.; Liver Cancer Center Heidelberg (LCCH), University Hospital Heidelberg, Heidelberg, Germany., Roessler S; Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, Heidelberg, Germany.; Liver Cancer Center Heidelberg (LCCH), University Hospital Heidelberg, Heidelberg, Germany., Utku N; Institute for Medical Immunology, Campus Virchow, Berlin, Charité, Germany. nalan.utku@charite.de.; CellAct Pharma GmbH, Otto Hahn Strasse 15, 44227, Dortmund, Germany. nalan.utku@charite.de.

Publikováno v: Scientific reports [Sci Rep] 2019 Mar 13; Vol. 9 (1), pp. 4338. Date of Electronic Publication: 2019 Mar 13.